BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Secures FDA Agreement on Integrated Safety Plan for Buntanetap NDA Submission 

Posted

Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company, announced that the U.S. Food and Drug Administration (“FDA”) has agreed to its Integrated Summary of Safety (“ISS”) plan for buntanetap, an investigational once-daily treatment for Alzheimer’s and Parkinson’s diseases. The agreement supports the company’s strategy to combine safety data from both clinical programs into a unified database for its planned New Drug Application (“NDA”). The FDA also agreed to the proposed integration of pooled data using standardized analysis datasets and provided statistical recommendations that Annovis plans to incorporate into its final safety analysis.

The integrated analysis will include three randomized, double-blind, placebo-controlled studies and one open-label extension study, spanning completed and ongoing clinical trials. Annovis anticipates that more than 1,600 participants will have received buntanetap by the six-month data readout from its ongoing Phase 3 DUET-AD study. The company plans to submit its NDA following that readout, using the combined safety database to support its regulatory submission.

To view the full press release, visit https://ibn.fm/zIAXZ

About Annovis

Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). The Company’s lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients.

For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.

NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWireAustin, Texaswww.BioMedWire.com512.354.7000 OfficeEditor@BioMedWire.com

BioMedWire is powered by IBN